If you are using orphan drug prices as a barometer-of-sorts to measure the broader US pricing climate, then you can rest easy following approval of Vertex’s cystic fibrosis treatment Orkambi. Set to be launched with a list price of $259 000 per-patient, per-year, Orkambi is priced at the top end of expectations. Subscription required to read more, here. (Source: FirstWord)
You are here: / / How Elastic is America’s Orphan Drug Pricing?